|Publication number||US3699229 A|
|Publication date||Oct 17, 1972|
|Filing date||Dec 18, 1970|
|Priority date||Dec 18, 1970|
|Publication number||US 3699229 A, US 3699229A, US-A-3699229, US3699229 A, US3699229A|
|Inventors||Nicholas Peter Plotnikoff|
|Original Assignee||Abbott Lab|
|Export Citation||BiBTeX, EndNote, RefMan|
|Patent Citations (1), Referenced by (13), Classifications (4)|
|External Links: USPTO, USPTO Assignment, Espacenet|
United States Patent Plotnikoff 51 Oct. 17, 1972 2-OXO-5-PHENYL-4-OXAZOLIDINONE  References Cited 0 AS AN PRE DE ss-ANT AGENT UNITED STATES PATENTS  Inventor: Nicholas Peter Plotnikoff, Village of r Lake Bl ff m 2,721,197 10/1955 'Sheehan ..260/ 239.l  Assignee: Abliott Laboratories, North a d, m s Friedman Chwago, Attorney-Robert L. Niblack  Filed: Dec. 18, 1970  ABSTRACT  Appl. No.: 99,725
Covers a method of treating patients exhibiting symptoms of depression by administering to said patients a U-S- t on 2 xo 5 phenyl 4 0x [51 Int. Cl. ..A6lk 27/00 azolidinone.  Field of Search ..424/272; 260/307 C 4 Claims, No Drawings 2-OXO-5-PI'IENYL-4-OXAZOLIDINONE AS AN ANTI-DEPRESSANT AGENT BACKGROUND OF THE INVENTION Patients suffering from depression manifest one or more of a variety of symptoms. Generally speaking'a depressed patient feels incapable of dealing with his responsibilities. The predominate symptoms of depression are hypochondria, anoxeria, insomnia, anergia, an-
hedonia and pessimism. patients suffering from these symptoms are usually treated with anti-depressants. The present invention provides a method for treating patients exhibiting these symptoms of depression.
BRIEF SUMMARY OF THE INVENTION This invention relates to a method of treating patients exhibiting symptoms of depression. More particularly, it relates to a method of administering to said patients at least an effective dosage of a composition of 2-ox0-5-phenyl-4-oxazolidinone.
DETAILED DESCRIPTION OF THE INVENTION The just-mentioned'compound is known and its preparation disclosed, for example in US. Pat. No. 2,721,197. Its structure is as follows:
CsHs-CH C= The above compound can be administered orally or by injection. For the latter, solutions or suspensions may be prepared by slurrying l-l0 percent of compound in water containing 0.1-2.0 percent of carboxymethylcellulose. Suspensions may also be prepared by using 0.05-0.5 percent tragacanth solutions. For oral administration, tablets, pills, or capsules are easily prepared. Tablets may be prepared to contain between 5 and 25 mg. of the active material together with the usual tableting adjuvants, e.g., coloring agents, flavoring agents, diluents, lubricants, carriers and, if desired, dispersing agents or release retardants. The compound may also be combined with other active compounds such as tranquilizers.
The anti-depression agent disclosed here when administered to mammals such as humans is effective in a dosage range of from about 0.1 toabout 200 mg./kg. of body weight daily, either in single or divided dosages. More often the daily dosage range is 0.1- mgJkg.
This oxazolidinone compound also exhibits a sedative-tranquilizing activity.
EXAMPLE 1 One excellent way of testing the compounds for its anti-depressant activity is via the modified dopa-test described by G. M. Everett et al., Proc. lst lntJSymp.
' ing: when dl-dopa is given to untreated mice, no
Antidepressant Drugs, p. 164 (19661.
The above-modified dopa-test is based on the followresponse occurs because of the inactivation of the dopa by endogenous monoamine oxidase. However, if mice are pretreated with a monoamine oxidaseinhibitor, such as an oral administration of 40 ing/kg. of pargyline hydrochloride and then given 200 mg./kg. of dldopa orally, along with a known anti-depressant drug,
0 the mice show maximum motor reaction, violent activity umping and fighting.
TABLE I I Modified Dopa Oral Dose (mgJkgl) Test Rating 2S 1 slight activity 50 2 moderate activity 2 moderate activity 200 3 marked activity Eight hours after administration the activity of this compound was shown as follows:
TABLE II Modified Dopa Oral Dose (mg.(kg.) Test Rating 25 2 moderate activity 50 2 moderate activity 100 2 moderate activity What is claimed is:
1. A method of treating a patient exhibiting symptomsof depression comprising administering to said patient at least an anti-depressant effective dosage of a composition comprising 2-oxo-5-phenyl-4-oxazolidinone.
2. The method'of claim 1 wherein said dosage range is from about 0.1 to about 200 mg. /kg. of body weight daily.
3. The method of claim 2 wherein said dosage range is 0.1-20 mg./kg.
4. The method of claim 1 wherein said compound is administered in a unit dosage form in a pharmaceutically-acceptable carrier, said carrier comprising a major portion of said dosage form.
' Q a s I a a:
|Cited Patent||Filing date||Publication date||Applicant||Title|
|US2721197 *||Jan 5, 1953||Oct 18, 1955||Bristol Lab Inc||Bicyclic lactams|
|Citing Patent||Filing date||Publication date||Applicant||Title|
|US4332952 *||Apr 23, 1981||Jun 1, 1982||Pfizer Inc.||Hypoglycemic 5-substituted oxazolidine-2,4-diones|
|US4342771 *||Apr 23, 1981||Aug 3, 1982||Pfizer Inc.||Hypoglycemic 5-substituted oxazolidine-2,4-diones|
|US4367234 *||Jan 2, 1981||Jan 4, 1983||Pfizer Inc.||Hypoglycemic 5-substituted oxazolidine-2,4-diones|
|US4381308 *||Mar 1, 1982||Apr 26, 1983||Pfizer Inc.||Hypoglycemic 5-substituted oxazolidine-2,4-diones|
|US4407811 *||Mar 1, 1982||Oct 4, 1983||Pfizer Inc.||Hypoglycemic 5-substituted oxazolidine-2,4-diones|
|US4431810 *||May 20, 1982||Feb 14, 1984||Pfizer Inc.||Intermediates for the preparation of 5-substituted oxazolidine-2,4-diones|
|US4565820 *||Jan 26, 1984||Jan 21, 1986||Pfizer Inc.||Hypoglycemic 5-pyrrolyl, indolyl and quinolyl substituted oxazolidine-2,4-diones and their use|
|US4689336 *||Oct 3, 1985||Aug 25, 1987||Pfizer Inc.||Hypoglycemic 5-substituted oxazolidine 2,4-diones|
|US4753956 *||May 28, 1987||Jun 28, 1988||Pfizer Inc.||Hypoglycemic 5-substituted oxazolidine-2,4-diones|
|US4812471 *||Feb 8, 1988||Mar 14, 1989||Pfizer Inc.||Hypoglycemic 5-(isoxazolyl or isothiazolyl)-oxazolidine-2,4-diones|
|DE3129275A1 *||Jul 24, 1981||Apr 22, 1982||Pfizer||Hypoglykaemische 5-substituierte oxazolidin-2,4-dione|
|DE3129309A1 *||Jul 24, 1981||Mar 18, 1982||Pfizer||Hypoglykaemische 5-substituierte oxazolidin-2,4-dione|
|EP0097453A2 *||Jun 9, 1983||Jan 4, 1984||Pfizer Inc.||Alicyclic substituted oxazolidine-2,4-diones having hypoglycemic activity|